Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs eBay Inc (EBAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs eBay Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while eBay Inc trades at $116.78 (market cap $52.04B). The key difference: eBay Inc is the larger of the two by market cap, and eBay Inc pays a 1.06% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EBAY | |
|---|---|---|
Market Cap | $39.89B | $52.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $118.96 |
52-Week Low | $278.09 | $76.79 |
Enterprise Value | $38.15B | $55.38B |
Volume | — | 5,186,418 |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EBAY trades at $117.20, down 0.11% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.66 beating expectations of $1.58, and maintains healthy profitability with 71.79% gross margins and 17.61% net income margin. Recent news highlights GameStop's ongoing takeover interest, creating significant market attention.
EBAY presents a mixed investment case with strong operational performance offset by takeover uncertainty. The stock trades above analyst consensus target of $109.56, suggesting limited near-term upside, while the potential acquisition creates both opportunity and execution risk. Key risks include competitive pressures in e-commerce and integration challenges from recent acquisitions like Depop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
